RecruitingPhase 1NCT07551336
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Studying High-grade astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing Biotech
- Intervention
- Dual-target CAR-NK cells(biological)
- Enrollment
- 36 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2028
Study locations (1)
- Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07551336 on ClinicalTrials.govOther trials for High-grade astrocytoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06214689IDH1 and OCT4 in High Grade AstrocytomaAssiut University
- RECRUITINGNANCT05979064Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)Northwell Health
- RECRUITINGPHASE2NCT05683808Venous Thromboembolism Prevention in Outpatients With GliomaUniversity of Vermont Medical Center